title: Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial.
abstract: BACKGROUND
  Outcomes in patients with ST-elevation myocardial infarction (STEMI) differ between those in clinical trials and those in routine practice, as well as across different regions. We hypothesized that adjustment for baseline risk would minimize such variations.
  
  
  METHODS
  The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction (ExTRACT-TIMI) 25 registry was an observational study of patients with STEMI presenting to hospitals participating in the ExTRACT-TIMI 25 randomized clinical trial. Consecutive patients with STEMI who were not enrolled in the trial were entered into the registry. Demographics, in-hospital therapies, and in-hospital events were collected. Baseline risk was assessed using the TIMI Risk Index for STEMI. To adjust for differences among the countries from which the patients presented, the gross national income per annum per capita (GNI) was used.
  
  
  RESULTS
  A total of 3726 patients were registered from 109 sites in 25 countries. Patients in the registry had a higher baseline risk than those in the trial; they had more extensive prior cardiac histories and more comorbidities. Unadjusted in-hospital mortality was higher in the registry (8.3%) than in the trial (6.6%) (hazard ratio, 1.30; P < .001); however, after adjusting for TIMI Risk Index, mortality was similar (hazard ratio(adj), 1.00; P = .97). The GNI was not significantly predictive of in-hospital mortality in the multivariable model of the registry.
  
  
  CONCLUSIONS
  Patients in the registry had higher mortality than those in the trial. This difference could be explained by the higher baseline risk of patients in the registry. After adjusting for baseline risk, the GNI of the country in which the patient presented did not contribute to predicting in-hospital mortality.
authors.affiliation: Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Steinberg
authors.forename: Nazanin
authors.initials: N
authors.lastname: Moghbeli
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Buros
authors.forename: Mikhail
authors.initials: M
authors.lastname: Ruda
authors.forename: Alexander
authors.initials: A
authors.lastname: Parkhomenko
authors.forename: B Soma
authors.initials: BS
authors.lastname: Raju
authors.forename: Armando
authors.initials: A
authors.lastname: García-Castillo
authors.forename: Marianna
authors.initials: M
authors.lastname: Janion
authors.forename: José C
authors.initials: JC
authors.lastname: Nicolau
authors.forename: Keith A A
authors.initials: KA
authors.lastname: Fox
authors.forename: David A
authors.initials: DA
authors.lastname: Morrow
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
authors.forename: Elliott M
authors.initials: EM
authors.lastname: Antman
mesh_terms: D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000401:mortality* / Q000628:therapy*; D015425:Myocardial Reperfusion; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents